Dianthus Therapeutics
DNTH
165 hedge funds and large institutions have $2.02B invested in Dianthus Therapeutics in 2025 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 75 increasing their positions, 27 reducing their positions, and 18 closing their positions.
178% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 27
156% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 18
18% more funds holding
Funds holding: 140 → 165 (+25)
10% more capital invested
Capital invested by funds: $1.84B → $2.02B (+$181M)
27% less funds holding in top 10
Funds holding in top 10: 11 → 8 (-3)
30.93% less ownership
Funds ownership: 145.48% → 114.56% (-31%)
65% less call options, than puts
Call options by funds: $1.05M | Put options by funds: $3.03M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$32.4M |
| 2 |
BlackRock
New York
|
+$22.3M |
| 3 |
Millennium Management
New York
|
+$20.2M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$18.2M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$17.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$48.7M |
| 2 |
VPC
Vestal Point Capital
New York
|
-$46.4M |
| 3 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$45.4M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$42.6M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$34M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
QC
176
Quadrature Capital
London,
United Kingdom
| – | -$549K | -13,939 | Closed |
|
|
OAC
177
OMERS Administration Corp
Toronto,
Ontario, Canada
| – | -$476K | -12,100 | Closed |
|
178
Raymond James Financial
St Petersburg,
Florida
| – | -$442K | -11,245 | Closed |
|
|
EI
179
Ethic Inc
New York
| – | -$218K | -5,530 | Closed |
|
|
TRCT
180
Tower Research Capital (TRC)
New York
| – | -$56.8K | -1,443 | Closed |
|
|
CWM
181
Crowley Wealth Management
Wilmington,
Delaware
| – | -$8.7K | -221 | Closed |
|
|
PS
182
Principal Securities
Des Moines,
Iowa
| – | -$433 | -11 | Closed |
|
|
MA
183
Montag & Associates
Atlanta,
Georgia
| – | -$355 | -9 | Closed |
|
DNTH Hedge Fund Activity: Q4 2025 in Review
165 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q4 2025, worth a combined $2.02B — up 9.8% from $1.84B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new DNTH positions and 18 closed out — a net gain of 28 holders — while 75 added to existing stakes and 27 trimmed.
The largest buyer was State Street, adding an estimated $32.4M. The largest seller was RA Capital Management, cutting an estimated $48.7M.
- 165 institutional investors held Dianthus Therapeutics (DNTH) as of Q4 2025, up from 140 in Q3 2025.
- Funds reported $2.02B of Dianthus Therapeutics stock for Q4 2025, up 9.8% quarter-over-quarter.
- 46 funds opened new Dianthus Therapeutics positions in Q4 2025 and 18 closed out, a net change of +28 holders.
- The largest Dianthus Therapeutics buyer in Q4 2025 was State Street, an estimated $32.4M added.
- The largest Dianthus Therapeutics seller in Q4 2025 was RA Capital Management, an estimated $48.7M sold.
Based on aggregated 13F filings for Q4 2025.